Welcome to Mesothelioma.net - Turning Hope and Faith into Action.

Italian Researchers Identify Factor Affecting Mesothelioma Aggressiveness

It is well known that some types of mesothelioma cells are more aggressive than others, and are likewise more resistant to certain therapies. A team of researchers from the University of Torino in Italy believe that they have found a cellular variant that may be responsible for these differences

There are three different cell types that have been identified in cases of mesothelioma. The most common is epithelioid mesothelioma, which is the cell type most responsive to treatment. Epithelioid is followed by biphasic mesothelioma, which appears in roughly 20 to 35 percent of cases and which represents a mix of epithelioid and sarcomatoid cells. Finally, there are sarcomatoid mesothelioma cells, which are the most difficult to treat. The researchers, led by Dr. Erika Ortolan of the Laboratory of Immunogenetics and oncologist Dr. Alice Giacomino, focused on a molecule called CD157 which is found in ovarian cancer.

Knowing that ovarian cancer cells and epithelial mesothelioma cells originate in the same place, the study tried to determine whether CD157 was also present in mesothelioma cell lines They found that in testing nine malignant pleural mesothelioma cell groups, four of them had high levels of CD 157. They also found it present in disproportionate levels in 85.2% of the mesothelioma tissues that they examined and that it was directly linked to clinical aggressiveness.  The researchers were able to manipulate the levels of CD157 in mesothelioma cells, and in doing so found that it had a direct impact on the cells growth, its propensity to metastasize, and its conversion into tumors. These effects were seen most often in biphasic mesothelioma cells. It was also noted that CD157 caused a decline in the effectiveness of platinum-based chemotherapy on the cells. This type of chemotherapy is generally the first line of defense in the treatment of mesothelioma patients.

In reviewing their results, which were published in the journal Oncotarget, the study’s authors wrote, “These findings indicate that CD157 is implicated in multiple aspects of malignant pleural mesothelioma progression and suggest that CD157 expression could be used to stratify patients into different prognostic groups or to select patients that might benefit from a particular chemotherapeutic approach.”

Terri Oppenheimer

Terri Oppenheimer is an independent writer, editor and proofreader. She graduated from the College of William and Mary with a degree in English. Her dreams of a writing career were diverted by a need to pay her bills. She spent a few years providing copy for a major retailer, then landed a lucrative career in advertising sales. With college bills for all three of her kids paid, she left corporate America for a return to her original goal of writing. She specializes in providing content for websites and finds tremendous enjoyment in the things she learns while doing her research. Her specific areas of interest include health and fitness, medical research, and the law.

Get Your FREE Resources Sent Overnight

resources-shot_optimized
  • New treatment options
  • Veterans benefits & claims
  • $30 Billion asbestos trust fund information

– Or Call –
1-800-692-8608


Site Navigation

Where can I

Get Additional Help?

For over 15 years, we’ve provided the best FREE resources to mesothelioma patients and loved ones. Our resources include information on the leading treatment options and best doctors in your area; lessons learned from survivors; claims and benefits specifically for Veterans; and how to access your share of billions of dollars in trust fund money.

Get Your FREE Resources Sent Overnight

resources-shot_optimized
  • New Treatment Options
  • Veteran's Benefits & Claims
  • $30 Billion Asbestos Trust Fund Information

– Or Call –
1-800-692-8608

We are here to help you

support_staff

If you've been diagnosed with asbestos-related cancer, contact us at 1-800-692-8608 to find out if you are eligible to receive compensation. You can also fill out the form above to receive FREE information.

Quick Compensation - $30 Billion Trusts
$30 Billion Asbestos Trusts
Get Started